Back to search results

Open-Label Extension Study of SNK01 for Alzheimer's Disease

This study is an extension of a previous trial, looking at the long-term safety of a treatment called SNK01 for people with Alzheimer's disease. SNK01 is a type of immunotherapy that uses your own natural killer (NK) cells, which are part of your immune system. You may be able to join if you are between 40 and 85 years old and meet other specific health requirements. The main goal of this study is to track any side effects from SNK01 over one year. The study is currently unclear on its recruitment status and plans to enroll 30 participants.

Study design
This is an open-label extension study, meaning both you and the study team will know you are receiving SNK01. It plans to include 30 participants.
What's involved
SNK01 will be given as an intravenous (IV) infusion every 3 weeks. Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will assess side effects for one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07228078

Open-Label Extension Protocol to SNK01-AD01 Study

Recruiting
PHASE2Ages 40–85InterventionalTreatment
NKGen Biotech, Inc.
~30 participants
Updated 2025-11-13 on ClinicalTrials.gov
What's tested:SNK01

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Measured over 1 Year

Conditions

Alzheimer Disease

Explore related trials

Alzheimer's Disease

Where it's being run

1 sites across 1 states
California1

Who to contact

Study Director
[email protected]
949-396-6830
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the subject).
Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc., guardian (must be always the same person)) who is in close contact with the patient, available on call and who is able to contribute to the assessment of the ratings of the functional endpoints at specific study visits. This person will be able to communicate in the language in which the participant is being assessed and should also serve as a backup contact for the study site.
Participants previously completed participation in study SNK01-AD01.

What this trial measures

  • Number of participants with treatment-related adverse events as assessed by CTCAE v5.01 Year

    Evaluate the safety and tolerability of SNK01 assessed by labs, PE and AEs